Alzheimer's drug slowed cognitive decline overall in trial, but with major side effects for some

An experimental Alzheimer's disease drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday.